OrphoMed
San francisco bay area pharmaceutical company focused on the development of novel.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$39.0m | Series A | ||
| Total Funding | 000k | ||
Related Content
OrphoMed is a clinical-stage biotechnology company specializing in the development of advanced treatments for gastrointestinal disorders using its proprietary dimer therapeutics platform. The company primarily targets patients suffering from irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Operating in the biopharmaceutical market, OrphoMed's business model revolves around the research, development, and commercialization of novel therapeutics. Revenue is generated through funding rounds, partnerships, and eventually, the sale of approved treatments. The company serves a niche market of patients with specific gastrointestinal conditions, aiming to provide best-in-class therapeutic options. Recent activities include securing a $39 million Series A financing round and presenting clinical trial results at various industry forums. OrphoMed's leadership includes experienced professionals like Gary M. Phillips, M.D., and Mark Sostek, M.D., who drive the company's strategic and clinical initiatives.
Keywords: biotechnology, gastrointestinal, dimer therapeutics, IBS-D, clinical trials, biopharmaceutical, chronic pain, cystic fibrosis, innovative treatments, proprietary platform.